[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 6243 Introduced in House (IH)]
<DOC>
118th CONGRESS
1st Session
H. R. 6243
To direct the Secretary of Labor to issue an occupational safety and
health standard that requires employers to keep opioid overdose
reversal drugs onsite and develop and implement training plans to
respond to drug overdose emergencies and to amend the Omnibus Crime
Control and Safe Streets Act of 1968 to expand the grants authorized
under the Comprehensive Opioid Abuse Grant Program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
November 6, 2023
Mr. Gallego (for himself and Mr. Nunn of Iowa) introduced the following
bill; which was referred to the Committee on Education and the
Workforce, and in addition to the Committee on the Judiciary, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To direct the Secretary of Labor to issue an occupational safety and
health standard that requires employers to keep opioid overdose
reversal drugs onsite and develop and implement training plans to
respond to drug overdose emergencies and to amend the Omnibus Crime
Control and Safe Streets Act of 1968 to expand the grants authorized
under the Comprehensive Opioid Abuse Grant Program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Overdose Reversal Medication Act''
or the ``ORM Act''.
SEC. 2. OPIOID OVERDOSE REVERSAL DRUG STANDARD.
(a) Interim Final Standard.--
(1) In general.--Not later than 1 year after the date of
enactment of this Act, the Secretary of Labor shall issue an
interim final standard on workplace availability of an opioid
overdose reversal drug or device--
(A) to require all employers to possess an opioid
overdose reversal drug or device on site, where the
required number of doses of such drug or device
required is determined on the basis of the number of
employees of the employer on site, type of occupation,
and an assessment of potential use;
(B) that establishes guidelines for training on--
(i) identifying signs and symptoms
indicating that usage of an opioid overdose
drug or device is necessary; and
(ii) how to administer such opioid overdose
reversal drug or device; and
(C) that provides for a period as determined
appropriate by the Secretary, not to exceed 1 year,
during which the Secretary shall prioritize technical
assistance and advice consistent with section 21(d) of
the Occupational Safety and Health Act of 1970 (29
U.S.C. 670(d)) to employers subject to the standard
with respect to compliance with the standard.
(2) Effective date of interim standard.--The interim final
standard shall--
(A) take effect on a date that is not later than 30
days after issuance;
(B) shall have the same legal effect as an
occupational safety and health standard as defined by
section 3 of the Occupational Safety and Health Act of
1970 (29 U.S.C. 652); and
(C) be in effect until the final standard described
in subsection (b) becomes effective and enforceable.
(3) Failure to promulgate.--If an interim final standard
described in paragraph (1) is not issued by the date that is 1
year after the date of enactment of this Act, the provisions of
this Act shall be in effect and enforced in the same manner and
to the same extent as any standard promulgated under section
6(b) of the Occupational Safety and Health Act (29 U.S.C.
655(b)) until such provisions are superseded in whole by an
interim final standard issued by the Secretary that meets the
requirements of paragraph (1).
(b) Final Standard.--Not later than 2 years after the date of
enactment of this Act, the Secretary of Labor shall, pursuant to
section 6 of the Occupational Safety and Health Act (29 U.S.C. 655),
promulgate a final standard on workplace availability of opioid
overdose reversal drugs or devices--
(1) for the purposes described in subsection (a)(1)(A);
(2) that shall include, at a minimum, requirements
contained in the interim final standard promulgated under
subsection (a); and
(3) be effective and enforceable in the same manner and to
the same extent as any standard promulgated under section 6(b)
of the Occupational Safety and Health Act of 1970 (29 U.S.C.
655(b)).
(c) Definitions.--In this section:
(1) Employee; employer.--The terms ``employee'' and
``employer'' have the meaning given such terms in section 3 of
the Occupational Safety and Health Act of 1970 (29 U.S.C. 652).
(2) Opioid overdose reversal drug or device.--The term
``opioid overdose reversal drug or device'' means an opioid
overdose reversal drug or device approved, licensed, cleared,
or otherwise authorized for marketing by the Food and Drug
Administration.
(3) Secretary.--The term ``Secretary'' means the Secretary
of Labor.
SEC. 3. EXPANSION OF THE COMPREHENSIVE OPIOID ABUSE GRANT PROGRAM.
Section 3021 of title I of the Omnibus Crime Control and Safe
Streets Act of 1968 (34 U.S.C. 10701(a)) is amended--
(1) in subsection (a), by adding at the end the following:
``(11) Developing, implementing, or expanding a program
(which may include demonstration projects) that--
``(A) provides training on carrying and
administering an opioid overdose reversal drug or
device approved, licensed, cleared, or otherwise
authorized for marketing by the Food and Drug
Administration for local businesses, individuals, or
other community entities that are likely to encounter
individuals with substance use disorders, but are not
eligible for other Federal grant programs or to receive
training or resources under such a grant program
related to substance use prevention and treatment; or
``(B) provides resources for employers,
individuals, or community entities described in
subparagraph (A) who have received training described
in subparagraph (A) to acquire, carry, and administer
such a drug or device.''; and
(2) by adding at the end the following:
``(g) Preferential Consideration.--In awarding grants under this
part, the Attorney General may give preferential consideration to an
application from an applicant in a State that has in effect a law that
exempts from criminal and civil liability individuals who carry or
administer in good faith an opioid overdose reversal drug or device
approved, licensed, cleared, or otherwise authorized for marketing by
the Food and Drug Administration, if such an individual has been
trained to carry or administer such drug or device.''.
<all>